Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/ TCF3-PBX1

S. Jeha, D. Pei, S. C. Raimondi, M. Onciu, D. Campana, C. Cheng, J. T. Sandlund, R. C. Ribeiro, J. E. Rubnitz, Scott Howard, J. R. Downing, W. E. Evans, M. V. Relling, C. H. Pui

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

To evaluate the impact of contemporary therapy on the clinical outcome of children with pre-B acute lymphoblastic leukemia (ALL) and the t(1;19)/TCF3/PBX1, we analyzed 735 patients with B-cell precursor ALL treated in four successive protocols at St Jude Children's Research Hospital. The 41 patients with the t(1;19) had a comparable event-free survival to that of the 694 patients with other B-cell precursor ALL (P=0.63; 84.2±7.1% (s.e.) vs 84.0±1.8% at 5 years). However, patients with the t(1;19) had a lower cumulative incidence of any hematological relapse (P=0.06; 0 vs 8.3±1.2% at 5 years) but a significantly higher incidence of central nervous system (CNS) relapse (P<0.001; 9.0±5.1% vs 1.0±0.4% at 5 years). In a multivariate analysis, the t(1;19) was an independent risk factor for isolated CNS relapse. These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse.

Original languageEnglish (US)
Pages (from-to)1406-1409
Number of pages4
JournalLeukemia
Volume23
Issue number8
DOIs
StatePublished - Jan 1 2009

Fingerprint

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Central Nervous System
Recurrence
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Lymphoid Precursor Cells
Incidence
Disease-Free Survival
Multivariate Analysis
Therapeutics
Research

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Jeha, S., Pei, D., Raimondi, S. C., Onciu, M., Campana, D., Cheng, C., ... Pui, C. H. (2009). Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/ TCF3-PBX1. Leukemia, 23(8), 1406-1409. https://doi.org/10.1038/leu.2009.42

Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/ TCF3-PBX1. / Jeha, S.; Pei, D.; Raimondi, S. C.; Onciu, M.; Campana, D.; Cheng, C.; Sandlund, J. T.; Ribeiro, R. C.; Rubnitz, J. E.; Howard, Scott; Downing, J. R.; Evans, W. E.; Relling, M. V.; Pui, C. H.

In: Leukemia, Vol. 23, No. 8, 01.01.2009, p. 1406-1409.

Research output: Contribution to journalArticle

Jeha, S, Pei, D, Raimondi, SC, Onciu, M, Campana, D, Cheng, C, Sandlund, JT, Ribeiro, RC, Rubnitz, JE, Howard, S, Downing, JR, Evans, WE, Relling, MV & Pui, CH 2009, 'Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/ TCF3-PBX1', Leukemia, vol. 23, no. 8, pp. 1406-1409. https://doi.org/10.1038/leu.2009.42
Jeha S, Pei D, Raimondi SC, Onciu M, Campana D, Cheng C et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/ TCF3-PBX1. Leukemia. 2009 Jan 1;23(8):1406-1409. https://doi.org/10.1038/leu.2009.42
Jeha, S. ; Pei, D. ; Raimondi, S. C. ; Onciu, M. ; Campana, D. ; Cheng, C. ; Sandlund, J. T. ; Ribeiro, R. C. ; Rubnitz, J. E. ; Howard, Scott ; Downing, J. R. ; Evans, W. E. ; Relling, M. V. ; Pui, C. H. / Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/ TCF3-PBX1. In: Leukemia. 2009 ; Vol. 23, No. 8. pp. 1406-1409.
@article{b9c4351fef004368942919ec64e9ddaa,
title = "Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/ TCF3-PBX1",
abstract = "To evaluate the impact of contemporary therapy on the clinical outcome of children with pre-B acute lymphoblastic leukemia (ALL) and the t(1;19)/TCF3/PBX1, we analyzed 735 patients with B-cell precursor ALL treated in four successive protocols at St Jude Children's Research Hospital. The 41 patients with the t(1;19) had a comparable event-free survival to that of the 694 patients with other B-cell precursor ALL (P=0.63; 84.2±7.1{\%} (s.e.) vs 84.0±1.8{\%} at 5 years). However, patients with the t(1;19) had a lower cumulative incidence of any hematological relapse (P=0.06; 0 vs 8.3±1.2{\%} at 5 years) but a significantly higher incidence of central nervous system (CNS) relapse (P<0.001; 9.0±5.1{\%} vs 1.0±0.4{\%} at 5 years). In a multivariate analysis, the t(1;19) was an independent risk factor for isolated CNS relapse. These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse.",
author = "S. Jeha and D. Pei and Raimondi, {S. C.} and M. Onciu and D. Campana and C. Cheng and Sandlund, {J. T.} and Ribeiro, {R. C.} and Rubnitz, {J. E.} and Scott Howard and Downing, {J. R.} and Evans, {W. E.} and Relling, {M. V.} and Pui, {C. H.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1038/leu.2009.42",
language = "English (US)",
volume = "23",
pages = "1406--1409",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/ TCF3-PBX1

AU - Jeha, S.

AU - Pei, D.

AU - Raimondi, S. C.

AU - Onciu, M.

AU - Campana, D.

AU - Cheng, C.

AU - Sandlund, J. T.

AU - Ribeiro, R. C.

AU - Rubnitz, J. E.

AU - Howard, Scott

AU - Downing, J. R.

AU - Evans, W. E.

AU - Relling, M. V.

AU - Pui, C. H.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - To evaluate the impact of contemporary therapy on the clinical outcome of children with pre-B acute lymphoblastic leukemia (ALL) and the t(1;19)/TCF3/PBX1, we analyzed 735 patients with B-cell precursor ALL treated in four successive protocols at St Jude Children's Research Hospital. The 41 patients with the t(1;19) had a comparable event-free survival to that of the 694 patients with other B-cell precursor ALL (P=0.63; 84.2±7.1% (s.e.) vs 84.0±1.8% at 5 years). However, patients with the t(1;19) had a lower cumulative incidence of any hematological relapse (P=0.06; 0 vs 8.3±1.2% at 5 years) but a significantly higher incidence of central nervous system (CNS) relapse (P<0.001; 9.0±5.1% vs 1.0±0.4% at 5 years). In a multivariate analysis, the t(1;19) was an independent risk factor for isolated CNS relapse. These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse.

AB - To evaluate the impact of contemporary therapy on the clinical outcome of children with pre-B acute lymphoblastic leukemia (ALL) and the t(1;19)/TCF3/PBX1, we analyzed 735 patients with B-cell precursor ALL treated in four successive protocols at St Jude Children's Research Hospital. The 41 patients with the t(1;19) had a comparable event-free survival to that of the 694 patients with other B-cell precursor ALL (P=0.63; 84.2±7.1% (s.e.) vs 84.0±1.8% at 5 years). However, patients with the t(1;19) had a lower cumulative incidence of any hematological relapse (P=0.06; 0 vs 8.3±1.2% at 5 years) but a significantly higher incidence of central nervous system (CNS) relapse (P<0.001; 9.0±5.1% vs 1.0±0.4% at 5 years). In a multivariate analysis, the t(1;19) was an independent risk factor for isolated CNS relapse. These data suggest that with contemporary treatment, patients with the t(1;19) and TCF3/PBX1 fusion have a favorable overall outcome but increased risk of CNS relapse.

UR - http://www.scopus.com/inward/record.url?scp=68749108126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68749108126&partnerID=8YFLogxK

U2 - 10.1038/leu.2009.42

DO - 10.1038/leu.2009.42

M3 - Article

VL - 23

SP - 1406

EP - 1409

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 8

ER -